Dinutuximab Beta at the HUS and the Toulouse Oncopole
NCT06275334 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2024-02-23
Summary
In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse.
Conditions
Sponsors & Collaborators
-
University Hospital, Strasbourg, France
lead OTHER
Eligibility
- Min Age
- 2 Years
- Max Age
- 25 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-28
- Primary Completion
- 2024-11-30
- Completion
- 2024-11-28
Countries
- France
Study Locations
More Related Trials
-
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
NCT07318831 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
NCT02693171 ·Status: TERMINATED
-
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
NCT03794349 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
NCT04385277 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease
NCT05272371 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
NCT02748135 ·Status: COMPLETED ·Phase: PHASE1
-
Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours
NCT00918320 ·Status: COMPLETED ·Phase: PHASE2
-
Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.
NCT05338541 ·Status: RECRUITING ·Phase: PHASE1
-
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296 ·Status: RECRUITING ·Phase: PHASE3
-
Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma
NCT00025649 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
NCT06995872 ·Status: RECRUITING ·Phase: PHASE1
-
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma
NCT01467986 ·Status: COMPLETED ·Phase: PHASE2
-
Therapy for Children With Advanced Stage Neuroblastoma
NCT01857934 ·Status: COMPLETED ·Phase: PHASE2
-
Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma
NCT00960739 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma
NCT02025881 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
NCT01175356 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
NCT02774421 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients
NCT03042429 ·Status: COMPLETED ·Phase: PHASE3
-
Parental Decision-Making for Children With Relapsed Neuroblastoma
NCT02282735 ·Status: ACTIVE_NOT_RECRUITING
-
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma
NCT00276679 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
NCT00601003 ·Status: COMPLETED ·Phase: PHASE2
-
Rapid Administration Pilot for Infusing Dinutuximab
NCT05421897 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant
NCT00417053 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
NCT00992173 ·Status: WITHDRAWN ·Phase: PHASE2